Understanding and Managing Weight Gain and Obesity in Psychiatry: Pharmacological Approaches
Obesity and weight gain is a major health problem in Australia, with an increasingly large proportion of the general population – around a third – being in the obese range (BMI >=30 kg/m2).
Obesity and weight gain is linked with a number of psychiatric issues, including depression; and many people living with obesity feel stigmatised and ostracised.
But in terms of a burden of obesity, people with serious mental illnesses such as schizophrenia stand out: in the Australian Study of High Impact Psychoses (SHIP), conducted in 2010, three-quarters of people with psychotic disorders were overweight or obese. 
Obesity, along with diabetes, hypertension, dyslipidaemia and cigarette smoking, contributes to the overall high cardiovascular risk burden associated with schizophrenia, in turn adding to decreased longevity.
Obesity is largely consequent upon overconsumption of energy-rich foods, and some of the medications we prescribe for people with schizophrenia can enhance cravings for ‘junk’ food, as well as having other effects that add to the obesity risk profile.
Weiss, C., Weiller, E., Baker, R. A., Duffy, R. A., Gwin, K. K., Zhang, P., & McQuade, R. D. (2018). The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies. International clinical psychopharmacology, 33(5), 255.
Larsen, J. R., Vedtofte, L., Jakobsen, M. S., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., … & Fink-Jensen, A. (2017). Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine-or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA psychiatry, 74(7), 719-728.
Svensson, C. K., Larsen, J. R., Vedtofte, L., Jakobsen, M. S., Jespersen, H. R., Jakobsen, M. I., … & Fink‐Jensen, A. (2019). One‐year follow‐up on liraglutide treatment for prediabetes and overweight/obesity in clozapine‐or olanzapine‐treated patients. Acta Psychiatrica Scandinavica, 139(1), 26-36.